NUVB
Nuvation Bio Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 82.70K | $409,370 | n/a | n/a |
| Q2 2026 | 95 | +2 | 157.33M | $893.25M | +5 | −5 |
| Q1 2026 | 98 | +3 | 147.71M | $634.66M | +12 | −9 |
| Q4 2025 | 94 | +2 | 141.34M | $1.26B | +2 | n/a |
| Q3 2025 | 19 | +1 | 120.52M | $443.85M | +2 | −1 |
| Q2 2025 | 15 | 0 | 120.03M | $233.06M | +1 | −1 |
| Q1 2025 | 12 | -1 | 18.55M | $32.01M | n/a | −1 |
| Q4 2024 | 13 | 0 | 18.40M | $47.86M | n/a | n/a |
| Q3 2024 | 12 | +1 | 12.76M | $28.26M | +1 | n/a |
| Q2 2024 | 11 | n/a | 9.41M | $26.24M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 82.70K | +1.1% | $409,370 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 230 holders, 219.97M shares, $906.24M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 100.00K sh · $709,240
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology